Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Lung Diseases 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Adenocarcinoma 1

Interventions

Carboplatin 18Pemetrexed 10Paclitaxel 6pembrolizumab 5Nivolumab 5Cisplatin 5Gemcitabine 4osimertinib 3entinostat 3camrelizumab 3atezolizumab 3Erlotinib Hydrochloride 3selpercatinib 2pralsetinib 2durvalumab 2apatinib 2Vinorelbine 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Drug Delivery Systems 2Docetaxel 2Bronchoscopy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2zipalertinib 1zimberelimab 1toripalimab 1taletrectinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Diseases × sitravatinib × Thoracic × Clear all
NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Yale University

Phase 2 Terminated
9 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡